Skip to main content

Website governance · effective 27 August 2026

Tracking should never be hidden behind vague language.

The current application does not include advertising or behavioural analytics. The Spotify episode player remains blocked until a visitor chooses to load it.

Effective | 27 August 2026No advertising or behavioural analyticsSpotify blocked until visitor choice

01 · Current boundary

What the application is designed to do today.

Cookies are small files. Similar browser storage can retain information between page requests. This storage may be essential to security or functionality. It may also be used for analytics, personalisation or advertising when it is not essential.

A source review of this website application has not identified a dedicated advertising tracker or behavioural analytics integration. Hosting and security infrastructure may still use request data or strictly necessary mechanisms to deliver and protect the site.

The AI Ethics Now page offers an optional Spotify player. The player is not requested from Spotify until a visitor selects Load Spotify player. If loaded, Spotify may process technical data or place cookies under its own privacy and cookie terms.

01

Essential processing

Hosting and security infrastructure may use temporary request or session mechanisms needed to deliver and protect the site.

Verify in production
02

Embedded documents

Viewing a signed PDF in the browser may use the browser's own document viewer and normal network request processing.

No behavioural purpose claimed
03

Spotify player

The external player remains blocked until a visitor chooses to load it. The episode can instead be opened directly on Spotify.

Visitor initiated
04

Enquiry forms

Form fields are submitted only when the visitor chooses to send an enquiry. The form is not a cookie preference control.

Active submission

02 · Control rule

New tracking requires disclosure and choice first.

Before introducing analytics, advertising, personalisation or similar technology that is not essential, NEUVIOR should identify the provider, purpose, data involved, duration, international transfer position and method for withdrawing consent.

Where consent is required, the control should offer a real choice before activation and make refusal as accessible as acceptance. A preference record should not be described as operational until it is implemented and tested.

Browser controls can also block or delete stored information, although doing so may affect functions that are strictly necessary for a service requested by the visitor.

Human decision requiredProceed only inside an evidenced and governed scope.
01

Inventory

Maintain a list of names, providers, purposes and expiry periods that has been verified against production.

Required before activation
02

Consent

Hold technologies that are not essential until an affirmative choice has been recorded.

No implied consent
03

Withdrawal

Provide an equally clear route to change or withdraw a previous choice.

Symmetric control

03 · Review and change

The deployed site is checked when the technology changes.

NEUVIOR will review the public domain and source when hosting, security, analytics or embedded media changes. Any technology that is not essential will remain blocked until the required disclosure and choice are in place.

If a future scan or provider change identifies a different use of browser storage, this notice and any required preference control will be updated before that use is activated.

Questions about the current website boundary can be sent to [email protected].

Make the next step useful

Bring the problem that needs a clearer decision.

Tell us what is stuck, what decision you need to make and what a better outcome would change. We will connect you to the most relevant NEUVIOR, PHARMORIS, media or investor route.

QUESTIONS · ANSWERED DIRECTLY

The useful answers, in one place.

Browse every question
01What is NEUVIOR?

NEUVIOR is a pharmaceutical company registered in Scotland. It is building capabilities across medicines intelligence, governed technology and longer term development. PHARMORIS is its immediate product priority.

02What does NEUVIOR build today?

NEUVIOR is developing PHARMORIS, a human-governed medicines operations system in controlled, non-production development. It is intended to connect evidence, decisions, accountable work and value review. No independent TRL, deployment, customer adoption or clinical validation is claimed.

03What is PHARMORIS by NEUVIOR?

PHARMORIS is a configurable medicines operations system under controlled development. It is designed to help authorised teams progress medicine opportunities from evidence linked to its source, through an owned ActionCase, a human decision, delivery and review.

04Who founded NEUVIOR?

Varun Sharma is the Founder, CEO and CTO of NEUVIOR and leads the company and PHARMORIS product architecture.

05Where does NEUVIOR have a presence?

NEUVIOR works across Glasgow, London and Mumbai. Glasgow is the company origin and registered Scottish base. London supports commercial activity led by the founder. Mumbai supports market engagement in India and relationships across the pharmaceutical sector. These are different forms of presence. They do not imply three registered offices or regulated facilities.